Wall Street brokerages forecast that Genprex Inc (NASDAQ:GNPX) will announce earnings of ($0.18) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Genprex’s earnings. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Genprex will report full-year earnings of ($0.56) per share for the current fiscal year. For the next year, analysts forecast that the company will report earnings of ($0.64) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Genprex.

Separately, Maxim Group began coverage on Genprex in a research note on Friday, September 14th. They issued a “buy” rating and a $5.00 price objective for the company.

Shares of Genprex stock opened at $1.74 on Friday. Genprex has a 52 week low of $1.51 and a 52 week high of $19.45.

About Genprex

Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.

Further Reading: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.